Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation

Abstract Background Tyrosine kinase inhibitors (TKIs) are effective therapies with demonstrated antineoplastic activity. Nilotinib is a second-generation FDA-approved TKI designed to overcome Imatinib resistance and intolerance in patients with chronic myelogenous leukemia (CML). Interestingly, TKIs...

Full description

Bibliographic Details
Main Authors: Osvaldo Contreras, Maximiliano Villarreal, Enrique Brandan
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Skeletal Muscle
Subjects:
Nilotinib
Skeletal muscle
Differentiation
Myoblasts
Proliferation
Tyrosine kinase inhibitors
Online Access:http://link.springer.com/article/10.1186/s13395-018-0150-5

Internet

http://link.springer.com/article/10.1186/s13395-018-0150-5

Similar Items